Liver-related complications in HIV-infected individuals

Infectious Diseases in Clinical Practice

Volumn 15, Issue 1, 2007, Pages 38-48

  Chun, Helen M ^a   Landrum, Michael L ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; CLEVUDINE; EFAVIRENZ; EMTRICITABINE; ENTECAVIR; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; TYZEKA; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EOSINOPHILIA; FEVER; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER FUNCTION TEST; LIVER TOXICITY; MORBIDITY; MORTALITY; NAUSEA; NONALCOHOLIC FATTY LIVER; RASH;

EID: 33846315807     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000246152.78893.40     Document Type: Article

References (150)

1. Fauci AS, Lane HC. Human immunodeficiency virus (HIV) diseases: AIDS and related disorders. In: Braunwald E, Fauci AS, Kasper DL, et al. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw- Hill; 2001:1852-1912.
2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
3. Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in HIV-infected subjects. AIDS Rev. 2002;4:27-35.
4. Thio C. Hepatitis B in the HIV-infected patient: epidemiology, natural history and treatment. Semin Liver Dis. 2003;23:125-136.
5. Hung C, Hsiao C. Isolated antibody to hepatitis B core antigen in individuals infected with HIV-1. Clin Infect Dis. 2003;37:1275-1276.
6. Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1 infected individuals. Clin Infect Dis. 2003;36:1602-1605.
7. Peters MG. Managing hepatitis B coinfection in HIV-infected patients. Curr HIV/AIDS Rep. 2005;2:122-126.
8. Kellerman S, Hanson D, McNaghten A, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis. 2003;188:571-577.
9. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005;19:221-240.
10. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593-601.
11. Puoti M, Torti, Bruno R, et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44(1 suppl):S65-S70. Epub 2005 Nov 28.
12. Lok A. Chronic hepatitis B. N Engl J Med. 2002;346:1682-1683.
13. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24:211-217.
14. Thio C, Seaberg E, Skolasky R. HIV-1, hepatitis B virus, and risk of liver-related mortality in the MACS. Lancet. 2002;360:1921-1926.
15. Di Martino V, Thevenot T, Colin J, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002;123:1812-1822.
16. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis. 1989;160:577-582.
17. Sinicco A, Raiteri R, Sciandra M. Co-infected and super-infection of hepatitis B virus in patients infected with HIV: no evidence of faster progression to AIDS. Scand J Infect Dis. 1997;29:111-115.
18. Sheng WH, Chen MY, Hsieh SZ, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis. 2004;38:1471-1477.
19. Lincoln D, Petoumenos K, Dore G. On behalf of the Australian HIV Observational Database. HIV Med. 2003;4:241-249.
20. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215-229.
21. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know now in 2005. Hepatology. 2006;43:172-181.
22. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis. Hepatology. 2001;34:617-624.
23. Sheng WH, Hung CC, Kao JH, et al. Clinical and virologic effect of chronic hepatitis D virus infection on patients with hepatitis B and HIV co-infection in the era of HAART. Poster 838 CROI 2006.
24. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol. 2006;44(suppl):S90-S94.
25. Nunez M, Puoti M, Camino N, et al. Treatment of chronic hepatitis B in the HIV-infected patients: present and future. Clin Infect Dis. 2003;37:1678-1685.
26. Mommeja-Marin H, Mondou E, Blum M, et al. Serum HBV-DNA as a marker of efficacy during therapy for chronic hepatitis B infection: analysis and review of the literature. Hepatology. 2003;37:1309-1319.
27. Piroth L, Grappin M, Buisson M, et al. Hepatitis B virus seroconversion in HIV-HBV co-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;23:356-357.
28. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005;12:333-345.
29. Dore G, Cooper D, Barrett C, et al. Dual efficacy of lamivudine treatment in HIV/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis. 1999;180:607-613.
30. Hoff J, Bani-Sadr F, Gassin M, et al. Evaluation of chronic HBV infection in coinfected patients receiving lamivudine as a component of anti-HIV regimens. Clin Infect Dis. 2001;32:963-969.
31. Benhamou Y, Bouchet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology. 1999;30:1302-1306.
32. Buti M, Esteban R. Drugs in development for hepatitis B. Drugs. 2005;65:1451-1460.
33. Gish R, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol. 2005;43:60-66.
34. Peters M, Hann H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126:91-101.
35. Nunez M, Perez-Olmeda M, Diaz B, et al. Activity of tenofovir on hepatitis B virus replication in HIV-coinfected patients failing or partially responding to lamivudine. AIDS. 2002;16:2352-2354.
36. Ristig M, Crippin J, Aberg J. Tenofovir dipivoxil fumarate therapy for chronic hepatitis B in HIV/HBV-coinfected individuals for whom interferon alpha and lamivudine therapy have failed. J Infect Dis. 2002;186:1844-1847.
37. Delaney W, Yang H, Miller M, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004;48:3702-3710.
38. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in HBV polymerase. Gastroenterology. 2003;125:292-297.
39. Villneneuve J, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003;39:1085-1089.
40. Locarnini S, Qi X, Arterbur S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [abstract]. Paper presented at: 40th Annual Meeting of the European Association for the Study of Liver Diseases; April 13-17, 2005; Paris, France.
41. Dore G, Cooper D, Pozniak A, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185-1192.
42. Peters M, Anderson J, Lynch P, et al. Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are co-infected with HIV: results of ACTG A5127 [abstract]. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infection; February 22-25, 2005; Boston, MA.
43. Bani-Sadr F, Palmer P, Scieux C, et al. Ninety-six week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild type hepatitis B virus. Clin Infect Dis. 2004;39:1062-1064.
44. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004;48:3498-3507.
45. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-1217.
46. MacDonald JA, Caruso L, Karayannis P, et al. Diminished responsiveness of make homosexual chronic hepatitis B virus carriers with HTLV III antibodies to recombinant alpha interferon. Hepatology. 1987;7:719-723.
47. Lai C, Gane E, Hsu C, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Presented at: 57th American Association for the Study of Liver Disease; October 27-31, 2006; Boston, MA.
48. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology. 2000;32:430-432.
49. Neau D, Schvoerer E, Robert D, et al. Hepatitis B virus exacerbation with a precore mutant virus following withdrawal of lamivudine in a HIV-infected patient. J Infect. 2000;41:192-194.
50. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis. 1999;28:1032-1035.
51. Lim S, Wai C, Rajnakova A, et al. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002;51:597-599.
52. Altfeld M, Rockstroh J, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs positive patient with AIDS following lamivudine withdrawal. J Hepatol. 1998;29:306-309.
53. Asmuth DM, Busch MP, Laycock ME, et al. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. Antiviral Res. 2004;63:123-131.
54. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2001;32:144-148.
55. Lin PC, Poh SB, Lee MY, et al. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol. 2005;81:349-351.
56. Wong EK, Bodsworth NJ, Slade MA, et al. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS. 1996;7:490-494.
57. Tedaldi E, Baker R, Moorman A, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004;38:1478-1484.
58. Welch K, Morse A. Improving screening and vaccination for hepatitis B in patients coinfected with HIV and hepatitis C. Am J Gastroenterol. 2002;97:2928-2929.
59. Overton ET, Sungkanuparph S, Powderly WG, et al. Undetectable HIV plasma RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005;41:1045-1048.
60. Quaglio G, Talamini G, Lugoboni F, et al. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction. 2002;97:985-992.
61. Wilson CM, Ellenberg JH, Sawyer MK, et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH Cohort. J Adolesc Health. 2001;29:123-129.
62. Keet IPM, van Doornum G, Safary A, et al. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS. 1992;6:509-522.
63. Collier AC, Corey L, Murphey VL, et al. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988;109:101-105.
64. Landrum ML, Rasnake MS, Bradley W, et al. The clinical efficacy of hepatitis B vaccination in HIV-1 infected individuals. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Co.
65. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices and the American Academy of Family Physicians. MMWR. 2002;51(No. RR-2):1-34.
66. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-Infected persons - 2002 Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR. 2002;51(No. RR-8):1-23.
67. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR. 1993;42(No. RR-5):1-18.
68. Mannucci PM, Zanetti AR, Gringeri A, et al. Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med. 1989;149:1333-1337.
69. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS. 1994;8:558-559.
70. Sherman KE, Rouster SD, Chung RT. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
71. Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV (Human Immunodeficiency Virus) Atlanta V. A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29:150-154.
72. Greub G, Ledergerber B, Grob P, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;365:1800-1805.
73. Tien PC. Veterans Affairs Hepatitis CRCP and National Hepatitis CPO. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol. 2005;100:2338-2354.
74. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609-629.
75. Bonacini M, Louie S, Bzowej N, et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039-2046.
76. Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol. 2000;38:575-577.
77. George SL, Gebhardt J, Klinzman D, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr. 2002;31:154-162.
78. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285-2293.
79. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058.
80. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS. 2004;18:2163-2170.
81. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol. 1998;28:945-950.
82. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-247.
83. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-1199.
84. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
85. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-569.
86. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:179-183.
87. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192:992-1002.
88. Anderson KB, Guest JL, Rimland D. Hepatitis C Virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA cohort study. Clin Infect Dis. 2004;39:1507-1513.
89. Rancinan C, Neau D, Saves M, et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS. 2002;16:1357-1362.
90. Dorrucci M, Valdarchi C, Suligoi B, et al. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS. 2004;18:2313-2318.
91. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162:2125-2132.
92. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206.
93. van Asten L, Verhaest I, Lamzira S, et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis. 2004;189:292-302.
94. Ahlenstiel G, Woitas RP, Rockstroh J, et al. CC-chemokine receptor 5 (CCR5) in hepatitis C - at the crossroads of the antiviral immune response? J Antimicrob Chemother. 2004;53:895-898.
95. Strader DB, Wright T, Thomas DL, et al. AASLD practice guideline: diagnosis, management and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
96. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
97. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.
98. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
99. Kim AI, Saab S. Treatment of hepatitis C. Am J Med. 2005;118:808-815.
100. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS. 2004;18:F21-F25.
101. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis. 2005;41:1806-1809
102. Bruix J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
103. Braitstein P, Palepu A, Dieterich D, et al. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS. 2004;18:2221-2234.
104. Braitstein P, Zala C, Yip B, et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis. 2006;193:259-268.
105. Miller MF, Haley C, Koziel MJ, et al. Impact of Hepatitis C Virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41:713-720.
106. Den Brinker M, Wit F, Wertheim-van Dillen P. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.
107. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182-189.
108. Monforte A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr. 2001;28:114-123.
109. Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18:2277-2284.
110. Aceti A, Pasquazzi C, Zechini B, et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002;29:41-48.
111. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19:585-592.
112. Kramer JR, Giordano TP, Souchek J, et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005;42:309-314.
113. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18:767-774.
114. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-1713.
115. Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis. 2003;23:167-172.
116. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis. 2003;23:173-182.
117. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 2003;23:183-194.
118. Dieterich DT, Robinson PA, Love J, et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38:s80-s89.
119. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38:s90-s97.
120. Sulkowski M, Thomas D, Chaisson R, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
121. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis. 2004;38:s49-s55.
122. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
123. Montaner JS, Cote HCF, Harris M, et al. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34:s85-s90.
124. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect Dis. 2001;33:1931-1937.
125. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 2001;15:717-723.
126. Boxwell D, Haverkos H, Struble K, et al. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 2001;49:1153-1156.
127. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35:538-539.
128. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects [see comment]. J Infect Dis. 2005;191:825-829.
129. Monier PL, Wilcox R. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults. Am J Med Sci. 2004;328:48-56.
130. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDs. 2005;19:356-365.
131. Tien PC, Grunfeld C. The fatty liver in AIDS. Semin Gastrointest Dis. 2002;13:47-54.
132. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50:171-180.
133. Trojan A, Kreuzer KA, Flury R, et al. Liver changes in AIDS. Retrospective analysis of 227 autopsies of HIV-positive patients. Pathologe. 1998;19:194-200.
134. Sutinen J, Hakkinen AM, Weterbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS. 2002;16:2183-2193.
135. Day L, Shikuma C, Gerschenson M. Mitochondrial injury in the pathogenesis of antiretroviral-induced hepatic steatosis and lactic acidemia. Mitochondrion. 2004;4:95-109.
136. Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab. 2003;88:627-636.
137. Ogedegbe AE, Thomas DL, Diehl AM. Hyperlactatemia syndromes associated with HIV therapy. Lancet Infect Dis. 2003;3:329-337.
138. Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis: a reappraisal. J Viral Hepat. 2006;13:73-80.
139. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
140. Oneta CM, Dufour JF. Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly. 2002;132:493-505.
141. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967.
142. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710-723.
143. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-335.
144. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-1219.
145. Brunt EM, Neuschwander-Tetri BA, Oliver D, et al. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol. 2004;35:1070-1082.
146. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society - USA panel. J Acquir Immune Defic Syndr. 2002;31:257-275.
147. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219-1230.
148. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquire Immune Defic Syndr. 2005;39:174-180.
149. Schewe CK, Maserati R, Wassmer G, et al. Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment. Clin Infect Dis. 2006;42:145-147.
150. Burgianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000.